Instruction for use: Monotard HM

ATX Code A10AD01 Human insulin

Active substance Cetrorelix Insulin biphasic [human biosynthetic]

Pharmacological group

Insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

E14 Unspecified diabetes mellitus

Severe vascular complication of diabetes, Diabetes, Diabetic asthenia, Thyroid dysfunction, Diabetes,Obesity in the background of diabetes

Composition and form of release

1 ml of the suspension for injection contains human insulin 40 or 100 IU (suspension of zinc-insulin, 30% amorphous and 70% crystalline); In bottles of 10 ml.

Characteristic

Human zinc-insulin suspension of medium duration of action.

pharmachologic effect

Pharmacological action - hypoglycemic.

Interacts with a specific receptor of the plasma membrane and penetrates into the cell, which activates the phosphorylation of cellular proteins, stimulates glycogen synthase, pyruvate dehydrogenase, hexokinase, inhibits fat lipase and lipoprotein lipase. In combination with a specific receptor facilitates the penetration of glucose into cells, enhances its assimilation by tissues and promotes conversion into glycogen. Increases the glycogen reserve in muscles, stimulates the synthesis of peptides.

Clinical Pharmacology

The effect develops in 2.5 hours, reaches a maximum after 7-15 hours and lasts 24 hours. In type I diabetes, basal insulin is used in combination with short-acting insulin. With diabetes mellitus type II - for both monotherapy and in combination with high-speed insulin.

Indications

Diabetes mellitus is insulin-dependent and insulin-independent with resistance to sulfonylurea derivatives, intercurrent diseases, operations and in the post-operation period, during pregnancy.

Contraindications

Hypoglycemia, insulinoma.

pregnancy and lactation

It is not contraindicated, but during pregnancy, dose adjustment is required.

Side effects

Hypoglycemic conditions, allergic reactions; Rarely - redness and lipodystrophy at injection sites.

Interaction

MAO inhibitors, non-selective beta-blockers, ACE inhibitors, salicylates, anabolic steroids, alcohol - increase, oral contraceptives, corticosteroids, thyroid hormones, thiazide diuretics, sympathomimetics - weaken the hypoglycemic effect.

Dosing and Administration

PC; Before use, the contents of the vial are gently mixed until uniformity of the suspension is achieved. The dose is determined individually. When transferring a patient from a highly purified pig to human insulin of the same type, the dose should remain unchanged; When switching from pig or mixed types of insulin, the dose is usually reduced by 10% (unless the total daily dose exceeds 0.6 IU / kg).

Overdose

Symptoms: development of hypoglycemia (cold sweat, palpitation, tremor, hunger, excitement, irritability, pallor, headache, drowsiness, movement uncertainty, speech and vision impairment, depression). Severe hypoglycemia can lead to temporary or permanent impairment of brain function, coma and death.

Treatment: sugar or glucose solution inside (if the patient is conscious), sc, v / m, or / in - glucagon or IV glucose.

Precautionary measures

Patients receiving 100 IU per day or more should be hospitalized when insulin is replaced. When changing insulin, careful monitoring of blood sugar should be carried out. The ability to drive after the transfer of patients to human insulin may temporarily worsen. The dose of the drug must be corrected for infectious diseases, surgical interventions, thyroid dysfunction, Addison's disease, hypopituitarism, renal failure, in persons over 65 years of age.

Storage conditions

At a temperature of 2-8 ° C. Protect from heat, sunlight and freezing.

Keep out of the reach of children.

Shelf life

2.5 years.

Do not use after the expiry date printed on the package.